Innova Biosciences expands UK facility and increases laboratory space
The move comes in response to increasing demand for its products and services.
Innova Biosciences has expanded its UK footprint to enable the company to increase its laboratory space.
Innova’s sales and marketing teams have moved from the Babraham Research Park to Ashwell Point in Sawston, accommodating another 2500 sq ft of office space to double the company’s footprint across the two sites. The move enables both extra laboratory and office space to allow for further growth as the company continues to expand.
Innova Biosciences are experts in easy-to-use, cutting-edge bioconjugation technologies and services, with the flexibility to support scientists from academia through to commercial manufacturing. Products are based on its antibody and protein labeling, nanoparticle, oligonucleotide labeling, and phosphate detection enzyme assay technologies. The move marks the next stage in the company’s development, and comes in response to increasing demand for its products and services.
Dr Nick Gee, CEO of Innova Biosciences, commented: “Innova has expanded its laboratory space to accommodate the need for increased and continuous development of new products based on our bioconjugation technology, in addition to the custom services offering which has also grown year on year.”
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.